stockrow
Saturday 7 November 2026
Export NTLA’s income statement to Excel — free account
Intellia Therapeutics, Inc.
NTLA Healthcare Biotechnology
Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024.
- Revenue
- −48.0%
- EPS
- +1.09%
- Free cash flow
- −11.1%
Quarter to September 2026, against a year earlier
11.35
0.25
+2.25%
Follow NTLA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
31.97 | 37.95 | 22.98 | 14.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.79) | (27.17) | (12.94) | (14.06) | |
P/B ratio |
2.76 | 3.10 | 2.45 | 1.45 | |
Price to Tangible BV |
2.76 | 3.10 | 2.45 | 1.45 | |
EV/Sales |
23.00 | 30.60 | 17.29 | 7.75 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.43) | (5.25) | (3.15) | (1.33) | |
EV/FCF |
(3.41) | (5.22) | (3.14) | (1.32) | |
Quick Ratio |
6.00 | 5.61 | 5.04 | 4.42 | |
Current Ratio |
6.31 | 6.65 | 6.10 | 5.08 | |
Net Debt/EBITDA |
0.00 | 3.96 | 3.82 | 4.85 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.07 | 0.08 | 0.07 | |
Operating CF/Net income |
0.67 | 0.78 | 1.22 | 0.72 | |
Capex/Depreciation |
— | (0.83) | (0.04) | (0.02) | |
Research and Development Expense of Revenue |
1,163.56% | 1,078.40% | 536.53% | 385.16% | |
Selling, General and Administrative Expense of Revenue |
644.17% | 493.85% | 231.55% | 143.70% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
200.98% | 236.00% | 89.57% | 72.72% | |
Graham Net Nets |
0.13 | 0.18 | 0.22 | 0.37 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(27.78%) | (19.86%) | (27.61%) | (42.60%) | |
Free Cash Flow Yield |
(21.12%) | (15.43%) | (23.94%) | (40.63%) | |
Revenue per Share |
0.05 | 0.06 | 0.13 | 0.21 | |
Operating CF per Share |
(0.61) | (0.62) | (0.99) | (0.64) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.61) | (0.64) | (0.99) | (0.64) | |
Cash per Share |
3.38 | 3.28 | 3.17 | 4.15 | |
Shareholders Equity per Share |
4.37 | 5.45 | 5.24 | 6.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.37 | 5.45 | 5.24 | 6.20 | |
Free Cash Flow |
(85.43) | (84.83) | (117.42) | (69.41) | |
Working Capital |
426.04 | 448.44 | 390.00 | 423.83 | |
Capital Expenditures |
— | (1.72) | (0.08) | (0.13) | |
Net Current Asset Value |
216.88 | 398.37 | 328.61 | 356.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.22 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.27 | 9.34 | 9.82 | 8.99 | |
Average Payables |
12.91 | 10.76 | 15.58 | 17.42 | |
Average Assets |
913.92 | 878.03 | 872.47 | 1,016.57 | |
Average Common Equity |
680.76 | 721.48 | 700.43 | 771.68 |
Columns are period end dates · fundamentals updated 5 Nov 2026